Biological Therapy for Inflammatory Bowel Disease in Children / 대한소아소화기영양학회지
Pediatric Gastroenterology, Hepatology & Nutrition
;
: 13-18, 2012.
Artigo
em Inglês
| WPRIM
| ID: wpr-48593
ABSTRACT
The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn's disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and 'Top-down' therapy are some of the topics covered in this review.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Terapia Biológica
/
Imunoglobulina G
/
Doenças Inflamatórias Intestinais
/
Doença de Crohn
/
Fator de Necrose Tumoral alfa
/
Infliximab
/
Fatores Imunológicos
/
Anticorpos Monoclonais
/
Necrose
Limite:
Criança
/
Humanos
Idioma:
Inglês
Revista:
Pediatric Gastroenterology, Hepatology & Nutrition
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS